- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00876148
Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting
April 3, 2009 updated by: Azienda Ospedaliera San Giovanni Battista
The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Torino, Italy
- Azienda ospedaliera S Giovanni Battista
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
A cohort of patients undergoing allografting for hematological malignancies
Description
Inclusion Criteria:
- All patients undergoing an allograft for hematological malignancies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
April 3, 2009
First Submitted That Met QC Criteria
April 3, 2009
First Posted (Estimate)
April 6, 2009
Study Record Updates
Last Update Posted (Estimate)
April 6, 2009
Last Update Submitted That Met QC Criteria
April 3, 2009
Last Verified
April 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Neoplasms
- Neoplasms by Site
- Hematologic Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hematologic Neoplasms
- Hepatitis B
- Hepatitis
- Hepatitis A
Other Study ID Numbers
- LAM Allo SCT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancies
-
Donghua ZhangNot yet recruitingCD7-Positive Hematological MalignanciesChina
-
Tel-Aviv Sourasky Medical CenterMeir Medical Center; Max Planck Institute for Infection BiologyUnknownPediatric Solid Malignancies | Pediatric Hematological MalignanciesIsrael
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineCompletedMyeloid Hematological MalignanciesUnited States
-
Centre Hospitalier Universitaire de BesanconTerminatedHematological Malignancies BFrance
-
AdaptimmuneTerminatedSolid and Hematological MalignanciesUnited States, Canada
-
Shanghai Chia Tai Tianqing Pharmaceutical Technology...Not yet recruitingPhase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological MalignanciesCD20-positive Hematological MalignanciesChina
-
CASI pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada
-
Institute of Hematology & Blood Diseases Hospital...Juventas Cell Therapy Ltd.AvailableRelapsed and Refractory Hematological MalignanciesChina
-
Shandong UniversityJuventas Cell Therapy Ltd.UnknownRelapsed or Refractory Hematological MalignanciesChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingAdvanced Solid Tumors and Hematological Malignancies